CL2020001264A1 - Compuestos y métodos sintéticos para la preparación de retinodes específicos del receptor x retinoide. - Google Patents

Compuestos y métodos sintéticos para la preparación de retinodes específicos del receptor x retinoide.

Info

Publication number
CL2020001264A1
CL2020001264A1 CL2020001264A CL2020001264A CL2020001264A1 CL 2020001264 A1 CL2020001264 A1 CL 2020001264A1 CL 2020001264 A CL2020001264 A CL 2020001264A CL 2020001264 A CL2020001264 A CL 2020001264A CL 2020001264 A1 CL2020001264 A1 CL 2020001264A1
Authority
CL
Chile
Prior art keywords
preparation
retinodes
methods
specific
synthetic compounds
Prior art date
Application number
CL2020001264A
Other languages
English (en)
Inventor
Roshantha A Chandraratna
Thomas Jacks
Peter Wade
Andrew Thompson
Vidyasagar Pradeep Vuligonda
Original Assignee
Io Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Therapeutics Inc filed Critical Io Therapeutics Inc
Publication of CL2020001264A1 publication Critical patent/CL2020001264A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/32—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions without formation of -OH groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/44—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by addition reactions, i.e. reactions involving at least one carbon-to-carbon double or triple bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/74—Separation; Purification; Use of additives, e.g. for stabilisation
    • C07C29/76—Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment
    • C07C29/86—Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment by liquid-liquid treatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/13—Monohydroxylic alcohols containing saturated rings
    • C07C31/133—Monohydroxylic alcohols containing saturated rings monocyclic
    • C07C31/1333—Monohydroxylic alcohols containing saturated rings monocyclic with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/13—Monohydroxylic alcohols containing saturated rings
    • C07C31/137—Monohydroxylic alcohols containing saturated rings polycyclic with condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/36—Polyhydroxylic alcohols containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/38—Alcohols containing six-membered aromatic rings and other rings and having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
    • C07C51/21—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen
    • C07C51/255—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen of compounds containing six-membered aromatic rings without ring-splitting
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan en la presente compuestos útiles para la preparación de compuestos que tienen actividad biológica similar a retinoides. Asimismo, se proporcionan procesos para la preparación de compuestos que tienen actividad biológica similar a retinoides. se proporcionan en la presente compuestos útiles para la preparacion de compuestos que tienen actividad biológica similar a retinoides. Asimismo se proporcionan procesos para la preparacion de compuestos que tienen actividad biológica similar a retinoides
CL2020001264A 2017-11-17 2020-05-13 Compuestos y métodos sintéticos para la preparación de retinodes específicos del receptor x retinoide. CL2020001264A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762588163P 2017-11-17 2017-11-17
US201862671137P 2018-05-14 2018-05-14

Publications (1)

Publication Number Publication Date
CL2020001264A1 true CL2020001264A1 (es) 2020-09-04

Family

ID=66534915

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001264A CL2020001264A1 (es) 2017-11-17 2020-05-13 Compuestos y métodos sintéticos para la preparación de retinodes específicos del receptor x retinoide.

Country Status (16)

Country Link
US (3) US10590059B2 (es)
EP (1) EP3710027A4 (es)
JP (2) JP2021503464A (es)
KR (1) KR20200084350A (es)
CN (2) CN111465402B (es)
AU (4) AU2018367653B2 (es)
CA (1) CA3082485A1 (es)
CL (1) CL2020001264A1 (es)
IL (5) IL298073B2 (es)
MX (1) MX2020005027A (es)
MY (1) MY196734A (es)
NZ (1) NZ763866A (es)
PH (1) PH12020550613A1 (es)
SG (1) SG11202003733RA (es)
WO (1) WO2019099920A1 (es)
ZA (3) ZA202003475B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1937244T3 (pl) 2005-09-30 2019-01-31 Io Therapeutics, Llc Leczenie nowotworu specyficznymi agonistami rxr
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
CN114904000A (zh) 2016-03-10 2022-08-16 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
MX2020003223A (es) 2017-09-20 2020-09-21 Io Therapeutics Inc Tratamiento de enfermedades con ésteres de agonistas de rxr selectivos.
WO2019099920A1 (en) 2017-11-17 2019-05-23 Io Therapeutics, Inc. Compounds and synthetic methods for the preparation of retinoid x receptor-specific retinoids
WO2023108012A1 (en) * 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist and taxanes in treating her2+ cancers
WO2023108015A1 (en) * 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers
TW202400548A (zh) * 2022-03-15 2024-01-01 美商Ｉｏ治療公司 Rxr促效劑鹽形式、其多形體及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917082A (en) * 1995-06-06 1999-06-29 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having retinoid-like biological activity
FR2752837B1 (fr) * 1996-09-02 1999-11-12 Cird Galderma Nouveaux composes modulateurs des recepteurs hormonaux, les compositions les comprenant et leur utilisation en therapie
US6048873A (en) 1998-10-01 2000-04-11 Allergan Sales, Inc. Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
US6147224A (en) * 1998-10-01 2000-11-14 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6720423B2 (en) 2002-04-30 2004-04-13 Allergan, Inc. Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6936636B2 (en) * 2003-06-26 2005-08-30 Allergan, Inc. 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
PL1937244T3 (pl) 2005-09-30 2019-01-31 Io Therapeutics, Llc Leczenie nowotworu specyficznymi agonistami rxr
EP1979347A2 (en) * 2006-01-30 2008-10-15 Irm Llc Polycyclic 1,2,3,4-tetrahydro-isoquinoline derivatives and compositions comprising them as ppar modulators
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
CN108289958A (zh) 2015-10-31 2018-07-17 Io治疗公司 使用rxr激动剂和甲状腺激素的组合治疗神经***紊乱
US20190365681A1 (en) 2015-10-31 2019-12-05 Io Therapeutics, Inc. Treatment of cancer with combinations of rxr agonists and thyroid hormones
US20180318241A1 (en) 2015-10-31 2018-11-08 Io Therapeutics, Inc. Treatment of nervous system disorders using thyroid hormone neutral doses of rxr agonists
CN114904000A (zh) 2016-03-10 2022-08-16 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
CA3016878C (en) 2016-03-10 2024-02-27 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
WO2019099920A1 (en) 2017-11-17 2019-05-23 Io Therapeutics, Inc. Compounds and synthetic methods for the preparation of retinoid x receptor-specific retinoids

Also Published As

Publication number Publication date
CN111465402B (zh) 2022-05-24
IL289991B (en) 2022-12-01
IL289991A (en) 2022-03-01
KR20200084350A (ko) 2020-07-10
CA3082485A1 (en) 2019-05-23
JP2024028755A (ja) 2024-03-05
AU2018367653B2 (en) 2020-11-12
IL274729A (en) 2020-07-30
ZA202305927B (en) 2024-01-31
NZ763866A (en) 2021-07-30
CN115010577A (zh) 2022-09-06
ZA202105006B (en) 2022-12-21
AU2021202348A1 (en) 2021-05-13
AU2023201963A1 (en) 2023-05-04
IL283282A (en) 2021-07-29
PH12020550613A1 (en) 2021-02-22
ZA202003475B (en) 2023-10-25
BR112020009571A2 (pt) 2020-11-03
SG11202003733RA (en) 2020-05-28
MY196734A (en) 2023-05-03
WO2019099920A1 (en) 2019-05-23
IL289991B2 (en) 2023-04-01
IL298073A (en) 2023-01-01
EP3710027A1 (en) 2020-09-23
IL298073B2 (en) 2024-05-01
IL283282B (en) 2022-02-01
IL304970A (en) 2023-10-01
AU2021202348B2 (en) 2023-01-05
AU2020250208A1 (en) 2020-11-05
CN111465402A (zh) 2020-07-28
AU2020250208B2 (en) 2021-05-20
AU2018367653A1 (en) 2020-05-07
IL274729B (en) 2021-06-30
US20210139404A1 (en) 2021-05-13
US20200190008A1 (en) 2020-06-18
US20190152888A1 (en) 2019-05-23
EP3710027A4 (en) 2021-09-29
IL298073B1 (en) 2023-10-01
JP2021503464A (ja) 2021-02-12
MX2020005027A (es) 2020-08-13
US10590059B2 (en) 2020-03-17
US10919835B2 (en) 2021-02-16

Similar Documents

Publication Publication Date Title
CL2020001264A1 (es) Compuestos y métodos sintéticos para la preparación de retinodes específicos del receptor x retinoide.
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CL2017003103A1 (es) Compuestos de heteroarilo para la inhibición de cinasa
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
BR112018002432A2 (pt) anticorpos de ligação à il-8 e usos dos mesmos
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CL2018003527A1 (es) Conjugados de anticuerpo anti-egfr y fármaco.
EP3370633A4 (en) ORTHOPEDIC FASTENER, HOLDER AND GUIDANCE
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112016011146A8 (pt) dispositivo para a reconstrução da pele
BR112017003334A8 (pt) Variantes de desintegrina e usos farmacêuticos destas
BR112018002382A8 (pt) Novos anticorpos anti-gvpi humano e usos dos mesmos
UY36602A (es) Variantes de protoxina-ii y métodos de uso
BR112017014598A2 (pt) métodos e usos para hidrólise de queratina
CL2020001753A1 (es) Composiciones y metodos para la liberación de ciclopropenos.
AR104591A1 (es) Piroglutamato de vortioxetina
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
AR100231A1 (es) Composiciones para el cuidado de las telas que comprenden polímeros de poliuretano, poliurea y/o poliuretanourea
CO2018007237A2 (es) Reguladores del cftr y métodos para su uso